Jewelfish study
WebM Scoto,12 on behalf of the JEWELFISH Study Group The JEWELFISH population is broad and heterogeneous with a high degree of motor impairment at baseline *Three patients in the nusinersen group had also received olesoxime previously. †One patient in the onasemnogene abeparvovec group received treatment with onasemnogene Web12 okt. 2024 · JEWELFISH (NCT03032172) – an open-label exploratory trial designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in people with SMA aged 6 months to 60 years who received other investigational or approved SMA therapies for at least 90 days prior to receiving Evrysdi. The study has completed recruitment …
Jewelfish study
Did you know?
Web14 apr. 2024 · The study drew attention because it involved the widest population among SMA-related trials. Roche announced the study's interim results at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference in March. The JEWELFISH trial evaluated Evrysdi in 174 patients aged six months to 60 years with Type 1-3 SMA who … Web26 jan. 2024 · A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy (Jewelfish) The safety and scientific validity of this study is the …
Web11 jun. 2024 · Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated with another SMA-targeting therapy, including nusinersen and onasemnogene abeparvovec, showed the safety profile of Evrysdi and increase in SMN protein levels are consistent … WebThe first study being presented was JEWELFISH, a trial evaluating the safety, tolerability and efficacy of risdiplam in people living with SMA Types 1-3, aged 1 to 60 years who had been previously treated with another SMA-targeting therapy, including nusinersen (Spinraza™) and onasemnogene abeparvovec (Zolgensma™).
Web11 jun. 2024 · Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated with another SMA-targeting therapy ... Webstudy to investigate the safety, tolerability, pharmacokinetics and PK/PD relationship of RO7034067 patients ... AVXS-101 or olesoxime (BP39054/JEWELFISH) Study 6 . Multi-centre, single-arm, open-label study to investigate the efficacy, safety and tolerability, and PK/PD of RO7034067 in infants genetically diagnosed with SMA and pre ...
Web12 okt. 2024 · JEWELFISH (NCT03032172) – an open-label exploratory trial designed to assess the safety, tolerability, pharmacokinetics and pharmacodynamics in people with …
Web2 okt. 2024 · Patients in the JEWELFISH study have previously been treated with nusinersen or other therapies. In August, the first patient was enrolled in the RAINBOWFISH trial, an open-label, single-arm, international, multi-center clinical study to investigate the efficacy, safety, pharmacokinetics and pharmacodynamics of risdiplam in infants with … the villages barsWeb24 jan. 2024 · A Study of Risdiplam (RO7034067) in Adult and Pediatric Participants With Spinal Muscular Atrophy (Jewelfish) January 19, 2024 updated by: Hoffmann-La Roche An Open-Label Study to Investigate the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of Risdiplam (RO7034067) in Adult and Pediatric … the villages bass proWeb15 jun. 2024 · Preliminary 12-month data from JEWELFISH, a trial in people with all types of SMA aged 6 months to 60 years previously treated with other SMA therapies, … the villages bbq bashWeb12 jun. 2024 · Enrollment for the JEWELFISH study, assessing safety and pharmacodynamics of risdiplam in previously treated patients with SMA, who are now receiving risdiplam, is complete (n=174). the villages bayberry floor planWebJEWELFISH is an open-label, noncomparative study of risdiplam in patients with SMA who were previously enrolled in Roche Study BP29420 (MOONFISH) with the splicing modifier RG7800 (RO6885247) (development discontinued) or previously treated with nusinersen, onasemnogene abeparvovec, or olesoxime (previous Roche acquired development … the villages bbsWebSUNFISH is a 2-part, placebo-controlled study in people with Type 2 or 3 spinal muscular atrophy (SMA). The trial included people 2 to 25 years: the first placebo-controlled trial in adults and children older than 9 years of age with SMA. Learn more about the trial Evrysdi improved or preserved motor skills the villages bathroom remodelingWeb11 jun. 2024 · Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced new interim data from two studies of Evrysdi® (risdiplam); JEWELFISH and RAINBOWFISH. Data from JEWELFISH, an ongoing open-label study primarily evaluating the safety of Evrysdi in people aged 1 to 60 years who have been previously treated with another SMA-targeting … the villages beach boys